학술논문

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
Document Type
Article
Author
Ponikowski, PiotrKirwan, Bridget-AnneAnker, Stefan DMcDonagh, TheresaDorobantu, MariaDrozdz, JarosławFabien, VincentFilippatos, GerasimosGöhring, Udo MichaelKeren, AndreKhintibidze, IrakliKragten, HansMartinez, Felipe AMetra, MarcoMilicic, DavorNicolau, José COhlsson, MarcusParkhomenko, AlexanderPascual-Figal, Domingo ARuschitzka, FrankSim, DavidSkouri, Hadivan der Meer, PeterLewis, Basil SComin-Colet, Josepvon Haehling, StephanCohen-Solal, AlainDanchin, NicolasDoehner, WolframDargie, Henry JMotro, MichaelButler, JavedFriede, TimJensen, Klaus HPocock, StuartJankowska, Ewa AAzize, GFernandez, AZapata, GOGarcia Pacho, PGlenny, AFerre Pacora, FParody, MLBono, JBeltrano, CHershson, AVita, NLuquez, HACestari, HGFernandez, HPrado, ABerli, MGarcía Durán, RThierer, JDiez, MLobo Marquez, LBorelli, RRHominal, MÁMetra, MAmeri, PAgostoni, PSalvioni, AFattore, LGronda, EGhio, STurrini, FUguccioni, MDi Biase, MPiepoli, MSavonitto, SMortara, ATerrosu, PFucili, ABoriani, GMidi, PPassamonti, ECosmi, Fvan der Meer, PVan Bergen, Pvan de Wetering, MAl-Windy, NYYTanis, WMeijs, MGroutars, RGEJThe, HKSKietselaer, Bvan Kesteren, HAMBeelen, DPWHeymeriks, JVan de Wal, RSchaap, JEmans, MWestendorp, PNierop, PRNijmeijer, RManintveld, OCDorobantu, MDarabantiu, DAZdrenghea, DToader, DMPetrescu, LMilitaru, CCrisu, DTomescu, MCStanciulescu, GRodica Dan, AIosipescu, LCSerban, DLDrozdz, JSzachniewicz, JBronisz, MTycińska, AWozakowska-Kaplon, BMirek-Bryniarska, EGruchała, MNessler, JStraburzyńska-Migaj, EMizia-Stec, KSzelemej, RGil, RGąsior, MGotsman, IHalabi, MShochat, MShechter, MWitzling, VZukermann, RArbel, YFlugelman, MBen-Gal, TZvi, VKinany, WWeinstein, JMAtar, SGoland, SMilicic, DHorvat, DTušek, SUdovicic, MŠutalo, KSamodol, APesek, KArtuković, MRužić, AŠikić, JMcDonagh, TTrevelyan, JWong, Y-KGorog, DRay, RPettit, SSharma, SKabir, AHamdan, HTilling, LBaracioli, LNigro Maia, LDutra, OReis, GPimentel Filho, PSaraiva, JFKormann, Ados Santos, FRBodanese, LAlmeida, DPrecoma, DRassi, SCosta, FKabbani, SAbdelbaki, KAbdallah, CArnaout, MSAzar, RChaaban, SRaed, OKiwan, GHassouna, BBardaji, AZamorano, Jdel Prado, SGonzalez Juanatey, JRGa Bosa Ojeda, FIGomez Bueno, MMolina, BDPascual Figal, DASim, DYeo, TJLoh, SYSoon, DOhlsson, MSmith, JGGerward, SKhintibidze, ILominadze, ZChapidze, GEmukhvari, NKhabeishvili, GChumburidze, VPaposhvili, KShaburishvili, TKhabeishvili, GParhomenko, OKraiz, IKoval, OZolotaikina, VMalynovsky, YVakaliuk, IRudenko, LTseluyko, VStanislavchuk, M
Source
The Lancet; December 2020, Vol. 396 Issue: 10266 p1895-1904, 10p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate the effect of ferric carboxymaltose, compared with placebo, on outcomes in patients who were stabilised after an episode of acute heart failure.